Omeros (NASDAQ:OMER) Shares Break Below Two Hundred Day Moving Average - Time to Sell?

Omeros logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Omeros shares fell below their 200-day moving average, trading as low as $13.07 and last at $13.21, versus the average of $13.80.
  • Analyst views remain broadly positive: the stock has a “Moderate Buy” consensus and a $30.33 average price target, though one firm downgraded its rating to Hold.
  • Omeros reported quarterly EPS of $0.06, beating estimates of $0.02, but revenue of $35.93 million came in below expectations of $37.28 million.
  • Five stocks to consider instead of Omeros.

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $13.80 and traded as low as $13.07. Omeros shares last traded at $13.21, with a volume of 2,019,480 shares trading hands.

Omeros News Roundup

Here's some of the latest news about OMER:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $33 price target, raising its FY2026 EPS estimate to a loss of $0.08 per share from a loss of $0.37, and increasing its FY2029 and FY2030 forecasts. Analyst forecasts for Omeros
  • Positive Sentiment: Cantor Fitzgerald reiterated a Buy rating, adding to the positive analyst commentary. Cantor Fitzgerald remains a Buy
  • Positive Sentiment: An earnings-call report highlighted growth for YARTEMLEA, which may support investor optimism about the product’s commercial prospects. Omeros earnings call highlights YARTEMLEA growth

Analyst Upgrades and Downgrades

A number of analysts have commented on OMER shares. Weiss Ratings raised Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Wall Street Zen downgraded Omeros from a "buy" rating to a "hold" rating in a report on Saturday. Cantor Fitzgerald reissued an "overweight" rating and issued a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. Finally, HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Omeros in a research report on Tuesday. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $30.33.

Read Our Latest Report on OMER

Omeros Trading Down 5.7%

The firm has a market capitalization of $956.27 million, a PE ratio of 13.76 and a beta of 2.96. The company has a fifty day moving average price of $17.83 and a two-hundred day moving average price of $13.80.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The biopharmaceutical company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The firm had revenue of $35.93 million for the quarter, compared to analysts' expectations of $37.28 million. As a group, equities research analysts predict that Omeros Corporation will post -0.08 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Arnold Hanish sold 10,000 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the director owned 5,000 shares in the company, valued at approximately $94,750. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Peter Cancelmo sold 25,000 shares of the business's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the sale, the vice president directly owned 200 shares of the company's stock, valued at approximately $3,708. This represents a 99.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 75,906 shares of company stock worth $1,438,705 over the last quarter. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Omeros

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in shares of Omeros by 85.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company's stock worth $1,897,000 after buying an additional 82,646 shares during the period. Bank of America Corp DE acquired a new stake in Omeros during the second quarter worth about $1,846,000. BlackRock Inc. bought a new position in Omeros in the 2nd quarter valued at approximately $57,484,000. Corient Private Wealth LP acquired a new position in shares of Omeros in the 2nd quarter valued at about $6,274,000. Finally, State Street Corp raised its holdings in Omeros by 20.9% during the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company's stock worth $22,062,000 after buying an additional 400,331 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

(Get Free Report)

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omeros Right Now?

Before you consider Omeros, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.

While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines